Alnylam Pharmaceuticals (ALNY) : Fridays money flow analysis of Alnylam Pharmaceuticals (ALNY) indicates the selling of stock on the strength of price. The investors sold the stock on every rise as seen in the downtick transactions of $3.81 million. In comparison, the inflow of money on upticks was a meager $2.42 million. The dollar value of composite uptick trades minus the downtick trades was negative $1.39 million. The uptick to downtick ratio of 0.64 in the money flow shows weakness. The downtick transaction value was high at $1.63 million, which denotes distribution on strength.. Hence, the net money flow in the stock was negative ($1.63 million). Alnylam Pharmaceuticals (ALNY) gained $0.13 at $65.1, a change of 0.2% over the previous days close.
Alnylam Pharmaceuticals (ALNY) : The consensus price target for Alnylam Pharmaceuticals (ALNY) is $114.5 for the short term with a standard deviation of $35.46. The most optimist securities analyst among the 8 who monitor the stock believes that the stock can reach $180, however, the pessimist price target for the company is $80.
Alnylam Pharmaceuticals (NASDAQ:ALNY): stock turned positive on Friday. Though the stock opened at $65.24, the bulls momentum made the stock top out at $65.85 level for the day. The stock recorded a low of $64.58 and closed the trading day at $65.49, in the green by 0.80%. The total traded volume for the day was 770,778. The stock had closed at $64.97 in the previous days trading.
In a related news, The Securities and Exchange Commission has divulged that Maraganore John, director officer (CEO) of Alnylam Pharmaceuticals, Inc., had unloaded 30,151 shares at an average price of $64.83 in a transaction dated on July 19, 2016. The total value of the transaction was worth $1,954,689.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.